Bionor announces the assembly of a world-leading clinical study advisory board to discuss a first proof of principle Phase II clinical study for Vacc-4x as a component in the Functional Cure of HIVScientific .2015
(Oslo, Norway, 5 May) Bionor Pharma ASA (OSE:BIONOR), a leading biotechnology company searching for breakthrough products for the treatment and prevention of life-threatening viral diseases, today announces the assembly of a successful clinical study advisory board meeting with the participation of some of the world’s most prominent scientific advisors in HIV Cure research. The purpose of the meeting was to advise on the design of a proof of principle clinical study of Bionor’s therapeutic T-cell vaccine candidate Vacc-4x together with a latency reversing agent.
Bionor announces promising results from an interim analysis of the functional cure HIV study REDUC Part BScientific .2015
Indicating killing of reactivated HIV virus and reduction in latent viral reservoir when patients receive the therapeutic vaccine Vacc-4x prior to romidepsin